Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer

European Journal of Cancer

Volumn 46, Issue 3, 2010, Pages 558-565

  McCloskey, Eugene ^a   Paterson, Alexander ^b   Kanis, John ^a   Tähtelä, Rita ^c   Powles, Trevor ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b TOM BAKER CANCER CENTRE   (Canada)

^c Mehilainen Oy   (Finland)

^d Parkside Oncology Clinic   (United Kingdom)

Author keywords

Bisphosphonate; Bone loss; Bone mineral density; Breast cancer; Clodronate; Metastases; Osteoporosis; Serum N terminal pro peptide of type I procollagen

Indexed keywords

AMINO TERMINAL PRO PEPTIDE OF TYPE I PROCOLLAGEN; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CLODRONIC ACID; PLACEBO; PROCOLLAGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE REMODELING; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; DOUBLE-BLIND METHOD; FEMALE; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 75149173381     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.12.003     Document Type: Article

References (31)

1. Pavlakis N., Schmidt R.L., and Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev (2005) CD003474
2. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 (1998) 357-363
3. Powles T., Paterson S., Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20 (2002) 3219-3224
4. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer ISRCTN83688026. Breast Cancer Res 8 (2006) R13
5. Kanis J.A., McCloskey E.V., Powles T., Paterson A.H., Ashley S., and Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79 (1999) 1179-1181
6. Chen Z., Maricic M., Bassford T.L., et al. Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 165 (2005) 552-558
7. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
8. McCloskey E., Selby P., Davies M., et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19 (2004) 728-736
9. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
10. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
11. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
12. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
13. Powles T.J., McCloskey E., Paterson A.H., et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90 (1998) 704-708
14. Seibel M.J. Molecular markets of bone turnover: Biochemical, technical and analytical aspects. Osteoporosis Int 10 Suppl. 6 (2000) S18-29
15. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1058
16. Lester J., Dodwell D., McCloskey E., and Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 31 (2005) 115-142
17. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., and Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 75 (1997) 602-605
18. Saarto T., Blomqvist C., Välimäki M., Mäkelä P., Sarna S., and Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15 (1997) 1341-1347
19. Delmas P.D., Balena R., Confravreux E., Hardouin C., Hardy P., and Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15 (1997) 955-962
20. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25 (2007) 829-836
21. Gnant M. Management of bone loss induced by aromatase inhibitors. Cancer Invest 24 (2006) 328-330
22. Li J., Mashiba T., and Burr D.B. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69 (2001) 281-286
23. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., and Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90 (2005) 1294-1301
24. Markiewicz M.R., Margarone III J.E., Campbell J.H., and Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 136 (2005) 1669-1674
25. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
26. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
27. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
28. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1 (1889) 571-572
29. Orr W., Varani J., Gondex M.K., Ward P.A., and Mundy G.R. Chemotactic responses of tumor cells to products of resorbing bone. Science 203 (1979) 176-179
30. Sasaki A., Williams P., Mundy G.R., and Yoneda T. Osteolysis and tumour growth are enhanced in sites of increased bone turnover. J Bone Miner Res 9 Suppl. 1 (1994) S294
31. Saarto T., Blomqvist C., Risteli J., Risteli L., Sarna S., and Elomaa I. Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br J Cancer 78 (1998) 240-245